Literature DB >> 20134461

Calcium-modulating cyclophilin ligand does not restrict retrovirus release.

Annika Kühl, Jan Münch, Daniel Sauter, Stephanie Bertram, Ilona Glowacka, Imke Steffen, Anke Specht, Heike Hofmann, Heike Schneider, Georg Behrens, Stefan Pöhlmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20134461     DOI： 10.1038/nm0210-155

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  10 in total

1.  An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein.

Authors:  Stuart J D Neil; Virginie Sandrin; Wesley I Sundquist; Paul D Bieniasz
Journal:  Cell Host Microbe       Date:  2007-09-13       Impact factor: 21.023

2.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

3.  HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor.

Authors:  Christine Goffinet; Ina Allespach; Stefanie Homann; Hanna-Mari Tervo; Anja Habermann; Daniel Rupp; Lena Oberbremer; Christian Kern; Nadine Tibroni; Sonja Welsch; Jacomine Krijnse-Locker; George Banting; Hans-Georg Kräusslich; Oliver T Fackler; Oliver T Keppler
Journal:  Cell Host Microbe       Date:  2009-03-19       Impact factor: 21.023

4.  Identification of calcium-modulating cyclophilin ligand as a human host restriction to HIV-1 release overcome by Vpu.

Authors:  Vasundhara Varthakavi; Ellen Heimann-Nichols; Rita M Smith; Yuehui Sun; Richard J Bram; Showkat Ali; Jeremy Rose; Lingmei Ding; Paul Spearman
Journal:  Nat Med       Date:  2008-05-25       Impact factor: 53.440

5.  The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.

Authors:  Liwei Rong; Jianyong Zhang; Jennifer Lu; Qinghua Pan; René-Pierre Lorgeoux; Claudette Aloysius; Fei Guo; Shan-Lu Liu; Mark A Wainberg; Chen Liang
Journal:  J Virol       Date:  2009-05-27       Impact factor: 5.103

6.  Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion.

Authors:  Eri Miyagi; Amy J Andrew; Sandra Kao; Klaus Strebel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

7.  Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants.

Authors:  Matthew W McNatt; Trinity Zang; Theodora Hatziioannou; Mackenzie Bartlett; Ismael Ben Fofana; Welkin E Johnson; Stuart J D Neil; Paul D Bieniasz
Journal:  PLoS Pathog       Date:  2009-02-13       Impact factor: 6.823

8.  Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.

Authors:  Bin Jia; Ruth Serra-Moreno; William Neidermyer; Andrew Rahmberg; John Mackey; Ismael Ben Fofana; Welkin E Johnson; Susan Westmoreland; David T Evans
Journal:  PLoS Pathog       Date:  2009-05-15       Impact factor: 6.823

9.  Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking.

Authors:  Richard S Mitchell; Chris Katsura; Mark A Skasko; Katie Fitzpatrick; David Lau; Autumn Ruiz; Edward B Stephens; Florence Margottin-Goguet; Richard Benarous; John C Guatelli
Journal:  PLoS Pathog       Date:  2009-05-29       Impact factor: 6.823

10.  Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion.

Authors:  Ravindra K Gupta; Stéphane Hué; Torsten Schaller; Ernst Verschoor; Deenan Pillay; Greg J Towers
Journal:  PLoS Pathog       Date:  2009-05-22       Impact factor: 6.823
  10 in total
  4 in total

1.  Misdirection of membrane trafficking by HIV-1 Vpu and Nef: Keys to viral virulence and persistence.

Authors:  Andrey Tokarev; John Guatelli
Journal:  Cell Logist       Date:  2011-05

Review 2.  Molecular aspects of cyclophilins mediating therapeutic actions of their ligands.

Authors:  Andrzej Galat; Jacqueline Bua
Journal:  Cell Mol Life Sci       Date:  2010-07-04       Impact factor: 9.261

3.  The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin.

Authors:  Annika Kühl; Carina Banning; Andrea Marzi; Jörg Votteler; Imke Steffen; Stephanie Bertram; Ilona Glowacka; Andreas Konrad; Michael Stürzl; Ju-Tao Guo; Ulrich Schubert; Heinz Feldmann; Georg Behrens; Michael Schindler; Stefan Pöhlmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

4.  Influenza A virus does not encode a tetherin antagonist with Vpu-like activity and induces IFN-dependent tetherin expression in infected cells.

Authors:  Michael Winkler; Stephanie Bertram; Kerstin Gnirß; Inga Nehlmeier; Ali Gawanbacht; Frank Kirchhoff; Christina Ehrhardt; Stephan Ludwig; Miriam Kiene; Anna-Sophie Moldenhauer; Ulrike Goedecke; Christina B Karsten; Annika Kühl; Stefan Pöhlmann
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.